POS0915 ATP-BINDING CASSETTE G1 MEMBRANE TRANSPORTER-MEDIATED CHOLESTEROL EFFLUX CAPACITY INFLUENCES CORONARY ATHEROSCLEROSIS AND CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS

Background Cholesterol efflux capacity CEC measures the ability of high-density lipoprotein (HDL) to remove cholesterol from arterial wall macrophages upon interaction with membrane transporter proteins and reduce lipid content atherosclerotic plaques. inversely associated cardiovascular risk in general patients independently HDL levels. through ATP-binding-cassette G1 (ABCG1) is impaired RA, yet, its relationship atherosclerosis unknown. Objectives We here evaluated associations ABCG1-mediated coronary burden, plaque progression incident event RA. Methods Coronary was computed tomography angiography 140 without disease reassessed 99 after 83.6±4.0 months. measured Chinese hamster ovary cells, not transfected or ABCG1 gene, as percentage effluxed over total intracellular content. Logistic negative binomial regression tested binary count outcomes respectively. Cox association long-term risk. Results Mean (standard deviation [SD]) 4.71 (0.92)%. At baseline, likelihood extensive (≥5 plaques) (odds ratio 0.50 [95% CI 0.28-0.88]) numbers partially-calcified (rate [RR] 0.71 0.53-0.94]) low-attenuation plaques (RR 0.63 0.43-0.91]) ASCVD score statin use. There were no main effects ABCG1-CEC adjusted models. However, higher predicted decreased noncalcified calcified exclusively time-weighted mean prednisone dose (Figure 1A,B). Furthermore, at lower time-averaged CRP levels 1C). did have a effect on adjusting for score. any versus exposure during follow-up 1D,G), ≥1 1E,H), low (<median) baseline 1F,I) adjustments including (p-for-interaction=0.008, 0.021 0.033 respectively) Conclusion burden number high-risk baseline. It further conditionally cumulative inflammation dose. Notably, specifically users, those inflammation. Figure 1. significantly decreases formation new (A ) (B fully lesions daily average (C partially CRP. attenuates vs. (D,G ), (E,H high (F,I REFERENCES: NIL. Acknowledgements: Disclosure Interests George Karpouzas Speakers bureau: Sanofi/Genzyme/Regeneron, BMS, Consultant of: Janssen, Scipher, Grant/research support from: Pfizer, Bianca Papotti: None declared, Sarah Ormseth: Marcella Palumbo: Elizabeth Hernandez: Maria Pia Adorni: Francesca Zimetti: Matthew Budoff: Nicoletta Ronda: declared